For cancer patients in India, the struggle to stay alive is as much about the disease as about the arithmetic of fighting it. Experts call the government’s price caps a tokenistic, short-term measure. Patients will not benefit unless structural changes including tackling pricing at the manufacturing end, and large-scale government procurement to stabilise prices are put in place Will capping trade margins on 137 non-scheduled anti-cancer drugs bring down the overall cost.